TRDA Q3 2023 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$44M

Gross Profit

$22M49.3% margin

Operating Income

$14M32.0% margin

Net Income

$35M81.1% margin

EPS (Diluted)

$1.02

QoQ Revenue Growth

+140.7%

Cash Flow

Operating Cash Flow

-$24M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$485M

Total Liabilities

$238M

Stockholders' Equity

$247M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$44M	$0	—
Gross Profit	$22M	$0	—
Operating Income	$14M	-$26M	+154.0%
Net Income	$35M	-$25M	+241.1%

Revenue Segments

Upfront Payment Revenue

$40M100%